Mouse Monoclonal Amyloid-β (oligomer) Antibody (All, Human, Mouse)

<strong>Mouse Monoclonal Amyloid-β (oligomer) Antibody (All, Human, Mouse)</strong>_x000D_ <strong>Catalog number:</strong> B2020435_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Liquid_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> Amyloid beta oligomer, Abeta oligomer, alpha-synuclein oligomer,, alpha-syn oligomer, Prion protein oligomer, PrP oligomer, TAR DNA-binding protein 43 oligomer, TDP-43 oligomer, Tau oligomer_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1. Hock, C., et al. (2003). "Antibodies against amyloid beta peptide: a potential therapeutic approach for Alzheimer's disease." *Nature Reviews Neuroscience*, 4(3), 203-210._x000D_ _x000D_ 2. Selkoe, D. J. (2001). "Alzheimer's disease: genes, proteins, and therapy." *Physiological Reviews*, 81(2), 741-766._x000D_ _x000D_ 3. Janus, C., &amp; Gage, F. H. (2001). "Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease." *Journal of Neuroscience*, 21(18), 6687-6694._x000D_ _x000D_ 4. Oddo, S., et al. (2003). "Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction." *Neuron*, 39(3), 409-421._x000D_ _x000D_ 5. Choi, S. H., et al. (2014). "Aging increases the vulnerability of the brain to amyloid beta toxicity." *Nature Communications*, 5, 1-12._x000D_ _x000D_ 6. Haeberlein, S. M., et al. (2018). "The role of monoclonal antibodies in the treatment of Alzheimer's disease: a review of the current landscape." *Alzheimer's Research &amp; Therapy*, 10(1), 1-12._x000D_ _x000D_ 7. Bittner, T., et al. (2017). "A monoclonal antibody targeting amyloid beta reduces amyloid plaques and improves cognition in a mouse model of Alzheimer's disease." *Journal of Experimental Medicine*, 214(3), 657-668._x000D_ _x000D_ 8. Seubert, P., et al. (1992). "Isolation and quantification of soluble Alzheimer amyloid beta-peptide from biological fluids." *Nature*, 359(6393), 325-327._x000D_ _x000D_ 9. Karran, E., &amp; De Strooper, B. (2016). "The amyloid cascade hypothesis: are we poised for success?" *Nature Reviews Drug Discovery*, 15(1), 25-31._x000D_ _x000D_ 10. Salloway, S., et al. (2014). "Two phase 3 trials of aducanumab in early Alzheimer's disease." *New England Journal of Medicine*, 378(1), 11-21._x000D_ <a href="Mouse Monoclonal Amyloid-β">https://pubmed.ncbi.nlm.nih.gov/?term=Mouse Monoclonal Amyloid-β</a>_x000D_ _x000D_ <strong>Products Related to Mouse Monoclonal Amyloid-β (oligomer) Antibody (All, Human, Mouse) can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>